TMTy Moore

Ty Moore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ty Moore has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study

    by Alexander Douglas, Ty Moore, Griffin Hughes, Rigel Bacani, Brett Szymanski, Mackenzie Moody, Farzeen Syed, Matt Vassar

  • Open Access

    Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice

    by Sarah Blocker, Diana Kim, Courtney C. Cavalieri, Sabrina Cannon, Amanda Cass, Alexander Olinger, Bryce Bortka, Beth Gustafson, Allison Schepers, Jacob Hobbs, et al.


  • Open Access

    Core Outcome Set Measures are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study

    by Alexander Douglas, Ty Moore, Griffin Hughes, Rigel Bacani, Brett Szymanski, Mackenzie Moody, Farzeen Syed, Matt Vassar

    IntroductionRandomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standardization of PROs in research led to the development of The International Consortium for Health Outcomes Measurement (ICHOM). ICHOM has published literature describing their methodology and development of a breast cancer core outcome set (COS). Our primary aim was to investigate the completeness of reporting within breast cancer clinical trial registries after the publication of the ICHOM breast cancer COS. MethodsA cross-sectional analysis was performed using the ClinicalTrials.gov database. COS information and trial characteristics were extracted from the trial registries in a masked manner. The completeness of reporting of the COS was analyzed. ResultsAfter our final inclusion criteria was applied, our final sample of 237 RCTs were assessed. Systemic therapy was the most commonly reported type of intervention (216/237; 91.1%). The average completeness of reporting was only 28.5% across all of the intervention types, and over three-fourths of the RCTs reported less than half of the COS measures. ConclusionAs PROs and patient-centered healthcare are coming to the forefront of medicine, particularly in oncology, a standardized COS, like ICHOM’s, offers trialists an endorsed resource to thoroughly capture and report the patient perspective in clinical research. We have offered recommendations to improve the reporting of PRO measures to capture within breast cancer RCTs.

  • Open Access

    Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials

    by Varun Jhanji, Jacob Duncan, Taylor Gardner, Griffin K. Hughes, Ryan McIntire, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ty Moore, Elizabeth Garrett, et al.

    Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.

  • Open Access

    Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials

    by Varun Jhanji, Jacob Duncan, Taylor Gardner, Griffin K. Hughes, Ryan McIntire, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ty Moore, Elizabeth Garrett, et al.

    Supplementary Table S1: Clinical Trial Publications With Multiple Indications

  • Open Access

    Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials

    by Varun Jhanji, Jacob Duncan, Taylor Gardner, Griffin K. Hughes, Ryan McIntire, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ty Moore, Elizabeth Garrett, et al.

    Supplementary Figure S1: Flow diagram for study inclusion.

  • Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials

    by Varun Jhanji, Jacob Duncan, Taylor Gardner, Griffin K. Hughes, Ryan McIntire, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ty Moore, Elizabeth Garrett, et al.

    Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.


  • Health Inequities in the Epidemiology, Diagnosis, Treatment, and Outcomes of Plastic Surgery: A Scoping Review

    by Ty Moore, Danya Nees, Samuel Jacobsen, Andriana Peña, Reece Anderson, Elizabeth Garrett, Jordan Staggs, Philo Waters, Mitchell Love, Bryan Dunford, et al.

    Background: Plastic surgery is routinely sought after for the treatment of breast cancer, cleft lip and palate, and gender-affirming care. Inequities exist in plastic surgery in regard to the epidemiology, diagnosis, treatment, and outcomes experienced by patients. The purpose of our scoping review was to (1) outline current literature addressing health inequities in plastic surgery and (2) draw attention to the gaps in this literature. Methods: This scoping review was developed following guidelines from the Joanna Briggs Institute and PRISMA extension for scoping reviews. An initial search of MEDLINE (via PubMed), Ovid Embase, Cochrane Database of Systematic Reviews, and Scopus databases was performed to locate published articles on health inequities in plastic surgery. Articles had to address at least one of the National Institutes of Health's inequity groups we examined. Results: After reviewing full text, 153 studies were included in our final sample. We found race/ethnicity (94/153) and age (90/153) to be the 2 most commonly evaluated inequities in the scoping review. We discovered that patient populations that were older had public or no insurance and/or were in historically marginalized racial/ethnic groups were often less likely to be offered plastic surgery treatments. Conclusion: This scoping review describes the current literature on health inequities in plastic surgery and highlights gaps in the literature that warrant further research. We found significant findings regarding how vulnerable patient populations are affected by health inequities. Research should be conducted to investigate these inequities more thoroughly and discover the best solutions to bridge the gaps in providing equitable care.


  • Open Access

    Discontinuation and nonpublication analysis of chronic pain randomized controlled trials

    by Samuel M. Jacobsen, Ty Moore, Alexander Douglas, Drew Lester, Austin L. Johnson, Matt Vassar

    Introduction: The primary objective of this cross-sectional analysis is to evaluate rates of discontinuation and nonpublication of Randomized controlled trials (RCTs) of therapeutic interventions to treat chronic pain. Methods: Using ClinicalTrials.gov, a sample was obtained which included clinical trials pertaining to chronic pain. Trials were analyzed for publication status and completion status of each trial. If information was unavailable on the trial registry database, or could not be allocated through a systematic search, the corresponding trialist was contacted and data points were gathered. Results: In our final analysis of the 408 RCTs, we found that 281 (68.9%) were published in a peer-reviewed journal and 127 (31.1%) were unpublished trials. Of 112 discontinued trials, 59 (52.7%) reached publication. In addition, 221 of 296 completed trials (74.7%) were published, and 75 (25.3%) remained unpublished after trial completion. The most common listed reason for trial discontinuation was administrative recommendations (41 of 71 trials [57.7%]), while not receiving an email reply to our standardized email from the corresponding trialist was the most common result for trial nonpublication (49 of 88 trials [55.7%]). Clinical trials funded by nonindustry sponsors were more likely to reach publication than industry-funded clinical trials (unadjusted odds ratio 1.86 [95% CI, 1.18–2.95]; adjusted odds ratio 3.01 [95% CI, 1.76–5.14]). Conclusion: The rate of discontinuation of RCTs involving patients with chronic pain is concerning. Chronic pain affects many patients; thus, the importance of having quality data from clinical trials cannot be overstated. Our study indicates that chronic pain RCTs are frequently discontinued and their findings often go unpublished — all of which could provide crucial information to providers and patients regarding the treatment of chronic pain. We offer suggestions to enhance chronic pain RCT completion, thereby reducing the waste of resources in chronic pain research.